StockData
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO) stock

HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 13/3087% above fair value
$130.91−0.27 (-0.21%)

Close on Oct 30, 2026Market cap $14.86BP/E 38.6Yield –

Earnings

Halozyme Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 2, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$481.00M
+47.7% on a year earlier
Non-GAAP diluted earnings per share, Q2 FY2026
$2.28
$1.54 a year earlier
Latest guidance
Raised
Aug 6, 2026 · 8 items

Quarterly results

Revenue and earnings per share from each of Halozyme Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q3 FY2026ended Sep 30, 2026Nov 2, 2026Expected–––––
Q2 FY2026ended Jun 30, 2026Aug 6, 2026after the close$481.00M+47.7%$1.90$2.28Release
Q1 FY2026ended Mar 31, 2026May 11, 2026after the close$376.70M+42.2%$1.22$1.60Release
Q4 FY2025ended Dec 31, 2025Feb 17, 2026after the close$451.80M+51.6%-$1.20-$0.24Release
Q3 FY2025ended Sep 30, 2025Nov 3, 2025after the close$354.30M+22.1%$1.43$1.72Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025after the close$325.70M+40.8%$1.33$1.54Release
Q1 FY2025ended Mar 31, 2025May 6, 2025after the close$264.90M+35.2%$0.93$1.11Release
Q4 FY2024ended Dec 31, 2024Feb 18, 2025after the close$298.00M+29.6%$1.06$1.26Release
Q3 FY2024ended Sep 30, 2024Oct 31, 2024after the close$290.10M+34.3%$1.05$1.27Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024after the close$231.40M+4.7%$0.72$0.91Release
Q1 FY2024ended Mar 31, 2024May 7, 2024after the close$195.90M+20.9%$0.60$0.79Release
Q4 FY2023ended Dec 31, 2023Feb 20, 2024after the close$230.00M+27.1%$0.65$0.82Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Halozyme Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Total revenueFY2026$1.84B – $1.91B$1.71B – $1.81BRaisedAug 6, 2026
Total revenueFY2026$1.71B – $1.81B–NewFeb 17, 2026
Total revenue growthFY2026+31% – +37%+22% – +30%RaisedAug 6, 2026
Adjusted EBITDAnon-GAAPFY2026$1.23B – $1.28B$1.13B – $1.21BRaisedAug 6, 2026
Adjusted EBITDAnon-GAAPFY2026$1.13B – $1.21B–NewFeb 17, 2026
Adjusted EBITDA growthnon-GAAPFY2026+86% – +95%+71% – +83%RaisedAug 6, 2026
Non-GAAP diluted earnings per sharenon-GAAPFY2026$8.65 – $9.00$7.75 – $8.25RaisedAug 6, 2026
Non-GAAP diluted earnings per sharenon-GAAPFY2026$7.75 – $8.25–NewFeb 17, 2026
Non-GAAP diluted earnings per share growthnon-GAAPFY2026+108% – +117%+87% – +99%RaisedAug 6, 2026
Revenue from royaltiesFY2026$1.22B – $1.25B$1.13B – $1.17BRaisedAug 6, 2026
Revenue from royaltiesFY2026$1.13B – $1.17B–NewFeb 17, 2026
Revenue from royalties growthFY2026+41% – +43%–RaisedAug 6, 2026
Revenue from royalties YOY GrowthFY2026+30% – +35%–NewMay 11, 2026

Guidance vs results

The last range Halozyme Therapeutics gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Non-GAAP diluted earnings per share$6.10 – $6.50$4.13Σ4QBelow range
FY2025Revenue$1.39B – $1.40B$1.40BΣ4QWithin range
FY2025Revenue growth+51% – +52%+37.55%Σ4QBelow range

Guidance history

Every forecast Halozyme Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 6, 2026Adjusted EBITDA growthFY2026+86% – +95%Raised
Aug 6, 2026Adjusted EBITDAFY2026$1.23B – $1.28BRaised
Aug 6, 2026Non-GAAP diluted earnings per share growthFY2026+108% – +117%Raised
Aug 6, 2026Non-GAAP diluted earnings per shareFY2026$8.65 – $9.00Raised
Aug 6, 2026Revenue from royalties growthFY2026+41% – +43%Raised
Aug 6, 2026Revenue from royaltiesFY2026$1.22B – $1.25BRaised
Aug 6, 2026Total revenue growthFY2026+31% – +37%Raised
Aug 6, 2026Total revenueFY2026$1.84B – $1.91BRaised
May 11, 2026Adjusted EBITDA YOY GrowthFY2026+71% – +83%New
May 11, 2026Adjusted EBITDAFY2026$1.13B – $1.21BReaffirmed
May 11, 2026Non-GAAP diluted earnings per share YOY GrowthFY2026+87% – +99%New
May 11, 2026Non-GAAP diluted earnings per shareFY2026$7.75 – $8.25Reaffirmed
May 11, 2026Revenue from royalties YOY GrowthFY2026+30% – +35%New
May 11, 2026Revenue from royaltiesFY2026$1.13B – $1.17BNew
May 11, 2026Total revenue YOY GrowthFY2026+22% – +30%Lowered
May 11, 2026Total revenueFY2026$1.71B – $1.81BRaised
Feb 17, 2026Adjusted EBITDAFY2026$1.13B – $1.21BNew
Feb 17, 2026Non-GAAP diluted earnings per shareFY2026$7.75 – $8.25New
Feb 17, 2026Revenue from royaltiesFY2026$1.13B – $1.17BNew
Feb 17, 2026Total revenueFY2026$1.71B – $1.81BNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Halozyme Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
    News
  2. Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
    News
  3. HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
    Results
  4. HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
    Results
  5. HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
    Results
  6. Halozyme Raises 2025 Revenue Estimates,
    Results
  7. Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of
    News
  8. Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
    News
  9. HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS
    Results
  10. 8-K exhibit EX-99.1
    Update
  11. Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative
    Update
  12. HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS
    Results
  13. HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS
    Results
  14. HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE of $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA and NON-GAAP DILUTED EPS
    Results
  15. Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance
    Results